Biomatter Raises €16.2Mn Series A to Expand AI-Powered Enzyme Design Platform

The funding round was led by Astanor. Existing investors UVC Partners, Inventure and Metaplanet also participated in the round.

“Our goal is to make a custom enzyme as easy to order as a catalogue product, including for reactions that don’t have one today. This funding round lets us design enzymes from the chemistry up at a larger scale and get them into customers’ products faster,” said Laurynas Karpus, CEO and co-founder of Biomatter.

Harry Briggs, Partner, Astanor, said, “Enzymes power hundreds of billions of dollars in food production and biomanufacturing. But because improving them takes months or years of trial and error, companies settle for suboptimal enzymes. The constraint has been data. Until now, the field has been limited to training on what exists in nature. Biomatter has spent years generating data beyond nature, which allows them to design enzymes that never evolved. They have world-class customers returning again and again, across an array of industries. That is the clearest signal there is.”

Founded in 2018 by Donatas Repečka, Laurynas Karpus, Rolandas Meškys and Vykintas Jauniskis, Biomatter develops custom enzymes for companies in different industries. Its technology is used in areas such as biopharma, diagnostics, agriculture and industrial biotechnology.

The company has developed an AI-based platform to design and create new enzymes. It aims to make enzyme development faster and more accurate than traditional methods.

Biomatter's platform, called the Intelligent Architecture Platform, combines artificial intelligence with physics-based research. It uses the company's own technology and data to address common challenges in enzyme design, including accuracy and long development times.

Instead of starting with a natural enzyme and modifying it, Biomatter designs enzymes based on the specific chemical reaction a customer wants to achieve. This allows the company to create enzymes suited to particular products and industrial needs.

Biomatter says it has spent years building its own enzyme data, including information on designs that are not found in nature. This data helps its AI models explore new enzyme structures and sequences that traditional methods may not easily identify.

Biomatter will use the funding to build a new 2,000-square-metre (around 21,500-square-foot) facility in Vilnius. The design and testing centre is expected to open in 2027 and will allow the company to handle more development and testing work in-house.

The company aims to make enzyme development even faster with the new facility. Traditional enzyme development can take several months or even years. Biomatter says its current process takes only a few weeks, and the new centre could help reduce this time to just a few days.

Biomatter will also expand its sales team and strengthen its presence in the US, where around half of its customers are based. The company will continue investing in its AI platform and the enzyme data that supports its technology.

Read Also- Nebuly Raises €18.95Mn Series A to Help Enterprises Measure AI Agent ROI